Tags

Type your tag names separated by a space and hit enter

Current status of PET-imaging probes of β-amyloid plaques.
Arch Pharm Res. 2013 Oct; 36(10):1178-84.AP

Abstract

Alzheimer's disease (AD) is the most common form of dementia and is characterized by progressive cognitive decline and memory loss. One of pathological hallmarks of AD is the accumulation and deposition of β-amyloid (Aβ) plaques which is a potential target for the early diagnosis of AD. Positron emission tomography (PET), a sensitive radionuclide imaging technique, has provided opportunities to detect Aβ plaques of AD. PET-imaging probes of Aβ plaques have been extensively developed during the last decade. [(18)F]Florbetapir, the (18)F-labeled PET-imaging probe of Aβ plaques, was recently approved by US Food and Drug Administration. A number of follow-on PET-imaging probes are currently being developed in academia and pharmaceutical companies. This article will discuss the recent development of PET-imaging probes from [(11)C]PIB to [(18)F]Florbetapir, which are in clinic trials, and several follow-on probes in preclinical stage.

Authors+Show Affiliations

Department of Brain Science, Daegu Gyeongbuk Institute of Science & Technology (DGIST), 333, Tech Jungang Daero, Hyeonpung-Myeon, Dalseong-Gun, Daegu, 711-873, South Korea, jkoo001@dgist.ac.kr.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

23812777

Citation

Koo, Jaehyung, and Youngjoo Byun. "Current Status of PET-imaging Probes of Β-amyloid Plaques." Archives of Pharmacal Research, vol. 36, no. 10, 2013, pp. 1178-84.
Koo J, Byun Y. Current status of PET-imaging probes of β-amyloid plaques. Arch Pharm Res. 2013;36(10):1178-84.
Koo, J., & Byun, Y. (2013). Current status of PET-imaging probes of β-amyloid plaques. Archives of Pharmacal Research, 36(10), 1178-84. https://doi.org/10.1007/s12272-013-0193-4
Koo J, Byun Y. Current Status of PET-imaging Probes of Β-amyloid Plaques. Arch Pharm Res. 2013;36(10):1178-84. PubMed PMID: 23812777.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current status of PET-imaging probes of β-amyloid plaques. AU - Koo,Jaehyung, AU - Byun,Youngjoo, Y1 - 2013/07/01/ PY - 2013/05/09/received PY - 2013/06/16/accepted PY - 2013/7/2/entrez PY - 2013/7/3/pubmed PY - 2014/8/12/medline SP - 1178 EP - 84 JF - Archives of pharmacal research JO - Arch Pharm Res VL - 36 IS - 10 N2 - Alzheimer's disease (AD) is the most common form of dementia and is characterized by progressive cognitive decline and memory loss. One of pathological hallmarks of AD is the accumulation and deposition of β-amyloid (Aβ) plaques which is a potential target for the early diagnosis of AD. Positron emission tomography (PET), a sensitive radionuclide imaging technique, has provided opportunities to detect Aβ plaques of AD. PET-imaging probes of Aβ plaques have been extensively developed during the last decade. [(18)F]Florbetapir, the (18)F-labeled PET-imaging probe of Aβ plaques, was recently approved by US Food and Drug Administration. A number of follow-on PET-imaging probes are currently being developed in academia and pharmaceutical companies. This article will discuss the recent development of PET-imaging probes from [(11)C]PIB to [(18)F]Florbetapir, which are in clinic trials, and several follow-on probes in preclinical stage. SN - 0253-6269 UR - https://www.unboundmedicine.com/medline/citation/23812777/Current_status_of_PET_imaging_probes_of_β_amyloid_plaques_ L2 - https://dx.doi.org/10.1007/s12272-013-0193-4 DB - PRIME DP - Unbound Medicine ER -